TP-03 is a novel therapeutic that may offer treatment, if approved, for millions of patients with Demodex blepharitis.
Potentially 25 million patients with Demodex blepharitis in the US have been left without an FDA-approved treatment.
TP-03 can change that.
The active ingredient in TP-03 is lotilaner, a well characterized anti-parasitic agent that targets parasite-specific GABA-CI channels.
Please reach out to us using the form below.
Thank you for getting in touch! Someone from our team will respond shortly.